Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

FDA Is Urged To Make All Biosimilar Insulins Interchangeable

Jun 13 2019

• By Dave Wallace

Insulin — The Agency Is Evaluating Input On Insulins • Source: Shutterstock

Related Content

Mylan launches UK insulin glargine rival

Nov 23 2018

FDA’s Gottlieb Rolls Out A Raft Of Biosimilar Reforms

Dec 14 2018

Mylan Claims Victory On US Lantus Patents

Dec 13 2018

Mylan and Biocon have first pegfilgrastim in US

Jun 08 2018

Lilly Launches Lower-Priced Insulin Lispro

May 28 2019

FTC Warns FDA That Biologic Suffixes Will Curb Competition

May 22 2019

Interchangeable Insulins Could Be Left Out Of Diabetes Treatment ‘Ecosystem’

May 13 2019

Related Companies

Biocon, Ltd.

Viatris Inc.

Boehringer Ingelheim GmbH

Novartis AG

Eli Lilly and Company

Additional Topics

United States Regulation Biosimilars BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window